Navigation Links
Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy
Date:3/10/2008

NEW YORK, MARCH 6, 2008 A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a dose-dense regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity. While previous reports evaluating the cardiac effects of breast cancer treatments including trastuzumab and anthracyclines have shown an acceptable safety margin, the new study demonstrates an even lower risk of cardiac toxicity when standard doses of these drugs are administered more frequently over time a treatment plan called dose-dense, which has previously been shown to be a more effective anti-cancer approach.

The researchers used a dose-dense regimen of doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan or Neosar) followed by paclitaxel (Taxol) and found that the regimen when given every two weeks instead of three pairs safely with trastuzumab, a drug that is used to treat breast cancer in women whose tumors contain the protein receptor called HER2.

According to the findings, only 1.4 percent (one patient) of the 70 early-stage breast cancer patients treated with this regimen experienced congestive heart failure after 28 months of follow-up. This rate of cardiac toxicity is lower than the 4 percent threshold that is generally considered acceptable, and still lower than what was found in larger, previously published trials evaluating conventionally scheduled treatment with the use of trastuzumab.

The studys authors concluded that this dose-dense regimen combined with trastuzumab is a safe and effective way to treat women with early-stage HER2-positive breast cancer in the adjuvant setting and there is no need to forgo the use of this regimen because trastuzumab is also being administered.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3139
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Moderate alcohol consumption in middle age can lower cardiac risk
2. CardiacQA Surpasses 20,000 Client Generated Nuclear Cardiology Reports
3. Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results
4. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
5. Cardiac Science Corporation Selects Colubris Networks Wireless Solution for its Portable Electrocardiograph
6. $4 million award to improve detection of acute kidney injury after cardiac surgery
7. Cardiac Science to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
8. Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
9. Diagnostic Centers of America Retains NewsMark Public Relations to Showcase Its Rise as Only Medical Facility in South Florida With Worlds Most Advanced Cardiac Scanner
10. Gene predicts heart attack response and cardiac damage
11. Delray Beach Mayor Commemorates Diagnostic Centers of America (DCA) $2 Million Purchase from Siemens to Become Only Medical Facility in South Florida with Worlds Most Advanced Cardiac Scanner.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Based ... GROUP is internationally known as an industry leader specializing in surplus used medical ... selling more than 100,000 pieces of medical equipment every year. Erik Tivin, Chairman ...
(Date:9/2/2015)... ... 2015 , ... “ G-Hold ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... a tablet while reducing the likelihood of it dropping. , Tablets like the iPad ...
(Date:9/2/2015)... NC (PRWEB) , ... September 02, 2015 , ... ... IT and business services, has been named to the Inc. 5000 List, an ... has been publishing this list for 34 years, and this achievement puts Canopy ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... reputation for the telling the truth about medicine and health, truths that other ... video blog, where he plans to regularly debunk certain misconceptions surrounding cholesterol, metabolically ...
(Date:9/1/2015)... Miami, FL (PRWEB) , ... September 01, 2015 ... ... Food and Drug Administration (FDA) for the treatment of androgenic alopecia in adults, ... the brand new laser therapy cap, while also demonstrating its safety when used ...
Breaking Medicine News(10 mins):Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2
... from around the world met at a conference in ... in obesity. One line of discussion looked at factors ... it might be avoided. , Co-chairs of the conference, ... Research and Dr Jennifer Lovejoy from the University of ...
... directed KH Real Estate to issue a boil water advisory to ... Armstrong County, after samples taken by DEP tested positive for fecal ... received complaints from residents after two customers were hospitalized with intestinal ... for the bacteria. , , ...
... NEW YORK, Nov. 24, 2008 Forest Laboratories, Inc. (NYSE: ... and Trademark Office ("USPTO") has closed prosecution on the merits ... confirmed the validity of all of the previously granted claims. ... Intent to Issue Ex Parte Reexamination Certificate for U.S. Patent ...
... treatment system for advanced radiation therapy, today announced that Rafael (Ralph) ... effective December 1, 2008. Mr. Vaello, who will report to TomoTherapy ... the sales and field marketing group for Philips Healthcare’s Oncology Imaging ... ...
... celebrity trainer Ramona Braganza offers tips to stay trim over the holidays and ... without packing on the pounds. , , ... trimmings: , , , ... before you load your plate for dinner or head out to a holiday ...
... of them currently abstain from alcohol, drugs , , MONDAY, ... Americans over the age of 12 participate in self-help ... 2.3 million who currently abstain from use of these ... Monday by the federal Substance Abuse and Mental Health ...
Cached Medicine News:Health News:Why women should eat less, move more and consider wearing transdermal HRT patches during menopause 2Health News:Pennsylvania DEP Directs Shadyside Water Supply to Issue Boil Water Advisory 2Health News:USPTO Confirms Validity of Bystolic(R) Patent 2Health News: TomoTherapy Names Rafael Vaello Vice President of Global Sales : Former Philips Healthcare executive brings proven sales experience in oncology, imaging industries 2Health News:Tip Sheet: Celebrity Trainer, Ramona Braganza's Tips To Keep Off Those Extra Holiday Pounds 2Health News:5 Million People a Year Use Self-Help Addiction Programs 2
(Date:9/1/2015)... SAN DIEGO and BEDFORD, Mass. ... firm Robbins Arroyo LLP is investigating whether ... violated the Securities and Exchange Act of 1934.  ConforMIS ... Image-to-Implant technology platform to develop, manufacture, and sell joint ... fit each patient,s unique anatomy. View this ...
(Date:9/1/2015)... and Delaware , United ... (ASX: IVX; "Company" or "Invion"), is pleased to announce that ... securities to an institutional investor in the United ... proceeds of approximately A$1.001 million ("Placement") by the issue of ... of $0.014 per share. The Company has ...
(Date:9/1/2015)... and OR YEHUDA, Israel , Sept. ... HTWR ), a leading innovator of less invasive, ... of advanced heart failure, announced today that it has ... Cardio, Ltd . ("Valtech").  Valtech is a privately held ... and transcatheter valve repair and replacement devices for the ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... March 23 MicroMass Communications, Inc., a world leader in behavioral marketing, has been named agency of record ... new center and its mission of promoting the growth of North Carolina ,s advanced medical technologies industry. , ... ... , ...
... , March 23 Portola Pharmaceuticals, Inc. ... human Phase 1 trial in healthy volunteers of PRT062607, ... treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and ... In preclinical in vivo models of RA, ...
Cached Medicine Technology:MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 2MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 3MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 4Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications 2Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications 3Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications 4
... standard, corrected curve trial lenses are ground with ... Marco refractors and are invaluable in treating low ... other manufacturers contain a disproportionately large number of ... expensive to produce, and fewer lenses in the ...
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... has made the LM-770 the easiest ... Technicians can be trained to operate ... instruction. The instrument tells the user ... A flashing indicator alerts the user ...
... designed to perform precise and accurate ... one-third the space of traditional examinations. ... refractors, automatic or digital lensmeters and ... EPIC enables the operator to call ...
Medicine Products: